HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 02, February 2017 – War on CANCER       » Two Scientists Share China's Top Science Award       » China Donates Mobile Clinics to Kenya       » Cervical Cancer: A Preventable Disease       » One More Piece in the Puzzle of Liver Cancer Identified       » Smoking While Pregnant May Compromise Children's Kidney Function       » You Are What You Exhale      
BIOBOARD - EUROPE
Roche launches first sugar-transferase for new glyco-engineering portfolio
Roche launched its new alpha-2,6-Sialyltransferase for in vitro sialylation of glycoproteins and complex molecules as human monoclonal antibodies (mAbs). The enzyme, which is offered for research and pilot scale applications, is produced under animal-origin free conditions and offers a very high lot-to-lot consistency.       

“This launch is the first in a series to offer a complete glyco-engineering portfolio of key enzymes and activated sugars covering a broad spectrum of applications,” said Ruedi Stoffel, Head of Biochemical Reagents & Custom Biotech. “The initial feedback from bio-manufacturing customers showed that our continuous scientific and technical support throughout the up-scaling and development process differentiates Roche as a strong partner.”           

The alpha-2,6-Sialyltransferase delivers up to 95% bi-antennary sialylation of N-Glycan chains within 6 – 8 hours, a performance which is currently not offered by competitor products. It is based on a human genome sequence and expressed in mammalian expression systems. Over the coming months, Roche plans to complete the portfolio through launches of additional Sialyl-and Galactosyltransferases. 

Glycosylation is considered to be one of the main sources of biologics’ heterogeneity and is seen as a critical quality attribute by regulatory bodies. The implementation of Quality by Design Standards in the manufacturing of Active Pharmaceutical Ingredients such as mAbs with specific glycosylation patterns is expected to play a central role in future bio-manufacturing processes.

Click here for the complete issue.

NEWS CRUNCH  
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
news 6th Asia-Pacific Breast Cancer Summit to take place in Hong Kong
news MIT Hacking Medicine Robotics in Singapore!
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Traditional Chinese Medicines
April:
Diabetics Technology
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy